Request Demo

Last update 06 Apr 2025

Magrolimab

Last update 06 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-cd47 monoclonal antibody hu5f9-g4, Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer, Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2

+ [8]

Target

CD47

Action

inhibitors

Mechanism

CD47 inhibitors(Cluster of differentiation 47 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [4]

Active Indication

Multiple MyelomaDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma+ [4]

Inactive Indication

Acute Myeloid LeukemiaAdvanced Colorectal AdenocarcinomaAdvanced Malignant Solid Neoplasm+ [15]

Originator Organization

Stanford University

Active Organization

Gilead Sciences, Inc.

Ono Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Sequence Code 321801864H

Source: *****

Sequence Code 321801865L

Source: *****

Clinical Trials associated with Magrolimab

NCT05823480

/ WithdrawnPhase 1IIT

A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) with Azacitidine As Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS

This phase I trial studies how well the combination of magrolimab works with azacitidine after a donor stem cell transplant (allogeneic hematopoietic cell transplantation) in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Magrolimab is a type of protein called an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to protect themselves from the body's immune system. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. Azacitidine is a chemotherapy drug that may prevent the return of acute myeloid leukemia or myelodysplastic syndrome by working in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining magrolimab and azacitidine may kill more cancer cells after allogeneic hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.

Start Date09 Oct 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT05829434

/ WithdrawnPhase 2

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed "ELN 2022 Intermediate or Adverse-risk" AML or High Risk MDS Patients Intended to Undergo Allogeneic Stem Cell Transplantation, a Phase 2, Single-arm, Open-Label Study

Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who intend to undergo allogeneic stem cell transplantation

Start Date31 Mar 2024

Sponsor / Collaborator

Universität Leipzig

[+1]

NCT05807126

/ WithdrawnPhase 1IIT

A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors

This phase I/Ib trial studies the side effects and best dose of Hu5F9-G4 (magrolimab) when given in combination with olaparib for the treatment of patients with breast or castrate-resistant prostate cancer that have spread from where they first started (primary site) to other places in the body (metastatic) or have come back after a period of improvement (recurrent) and have mutations in the BRCA1/2 genes. Magrolimab is a monoclonal antibody with potential anticancer activity and the cability to stimulate the immune system and may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Combination therapy with magrolimab and olaparib may be safe and effective in treating BRCA-mutated metastatic or recurrent breast or castrate-resistant prostate cancer.

Start Date05 Mar 2024

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Magrolimab

100 Translational Medicine associated with Magrolimab

100 Patents (Medical) associated with Magrolimab

Literatures (Medical) associated with Magrolimab

01 Dec 2024·LEUKEMIA

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia

Review

Author: Patel, Shyam A ; Patel, Shyam A.

Patients with TP53 aberrations comprise the highest risk subset of all myeloid malignancies. The managerial conundrum of TP53-mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) stems from refractoriness to or relapse after conventional chemotherapy, as well as the limited translational success of investigational therapies targeting TP53-mutant cells. Thus far, no targeted therapies have been commercially approved for this mutational subset. As a result, management plans for patients with TP53-mutant MDS and AML are often driven by clinical judgment and/or physician preference rather than consensus guidelines backed by a rigorous evidence basis. This clinical case-based, evidence-driven review highlights the most salient data that guides the management of commonly encountered patient prototypes. This review discusses the therapeutic menu of first-line options that derive from multi-institutional experiences as well as from disease-centric consortia and discusses how these first-line options can be optimally tailored to heterogeneous groups of patients. The debate regarding whether allogeneic stem cell transplant should be offered to these patients is summarized. Finally, this review explores the recent unfortunate news of pauses in clinical trials for the leading investigational agents - eprenetapopt, magrolimab, sabatolimab, and idasanutlin - and offers solutions toward re-invigorating the pipeline of precision therapeutics in 2025.

26 Nov 2024·Blood Advances

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma

Article

Author: Popplewell, Leslie ; Hacohen-Kleiman, Gal ; Zhang, Yi ; Ghosh, Nilanjan ; Maakaron, Joseph E. ; Asch, Adam ; Roschewski, Mark ; Ku, Matthew ; Mehta, Amitkumar ; Keane, Colm ; Flinn, Ian W. ; Collins, Graham P. ; Advani, Ranjana ; Renard, Camille ; Huo, Yanan ; Smith, Sonali M.

Abstract:

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti–cluster-of-differentiation-47 antibody) plus rituximab (M+R) demonstrated ability to induce complete responses (CR) in R/R DLBCL. Here, we report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R, and initial safety and efficacy of M+R plus gemcitabine-oxaliplatin (M+R-GemOx), in R/R DLBCL. After magrolimab priming, 4 groups of patients received M+R, 10 to 45 mg/kg magrolimab with 375 mg/m2 rituximab; patients receiving M+R-GemOx received 30 or 45 mg/kg magrolimab with 375 mg/m2 rituximab, 1000 mg/m2 gemcitabine, and 100 mg/m2 oxaliplatin. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of 132 patients treated, 99 received M+R and 33 received M+R-GemOx. Most common any-grade TEAEs were fatigue (M+R, 40%; M+R-GemOx, 70%), infusion-related reactions (M+R, 39%), or anemia (M+R-GemOx, 70%). Treatment-related TEAEs led to magrolimab discontinuation in 7% (M+R) and 6% (M+R-GemOx). One death was considered treatment related (M+R-GemOx, colitis). M+R ORR was 24% (CR, 12%), and median DOR was 9.3 months. Median PFS and OS were 1.8 and 9.2 months, respectively. M+R-GemOx ORR was 52% (CR, 39%); 12-month DOR rate was 66.6% (95% confidence interval, 33.1-86.1). Median PFS and OS were 3.9 months and not reached, respectively. These results demonstrate that M+R with/without GemOx is well tolerated, and M+R-GemOx has clinical activity in patients with R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02953509.

26 Nov 2024·Blood Advances

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial

Article

Author: Popplewell, Leslie ; Su-Feher, Linda ; Ghosh, Nilanjan ; Advani, Ranjana ; Bartlett, Nancy L. ; Roschewski, Mark ; Renard, Camille ; Huo, Yanan ; Collins, Graham P. ; Flinn, Ian W. ; Hacohen-Kleiman, Gal ; Smith, Sonali M. ; Mehta, Amitkumar

Abstract:

Relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally considered incurable with current treatment options. Previous phase 1b/2 results showed combining magrolimab (anti–cluster-of-differentiation [CD] 47 antibody) with the anti-CD20 antibody rituximab (M+R) has antitumor activity against R/R iNHL. We report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R in R/R iNHL. After magrolimab priming, 4 patient groups in phase 1b M+R received 10 to 45-mg/kg magrolimab doses with 375 mg/m2 rituximab. Phase 2 explored 30 and 45 mg/kg magrolimab. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory analysis included circulating tumor DNA, biomarkers of magrolimab tumor penetration, and drug target expression assessments. Of 46 patients treated in phase 1b/2, 42 had follicular lymphoma and 4 had marginal zone lymphoma. All patients experienced ≥1 any-grade TEAE, and 44 reported ≥1 treatment-related TEAE. No additional toxicities were reported during long-term follow-up, and there were no treatment-related deaths. Median follow-up was 36.7 (range, 1.2-62.3) months. The ORR was 52.2%, with 30.4% achieving a complete response. The median DOR was 15.9 months, and median time-to-response was 1.8 months. Median PFS and OS were 7.4 (95% confidence interval, 4.8-13.0) months and not reached, respectively. These results demonstrate the long-term safety and efficacy of M+R in patients with iNHL and support further exploration of CD47-based treatment combinations. This trial was registered at www.ClinicalTrials.gov as #NCT02953509.

126

News (Medical) associated with Magrolimab

03 Feb 2025

·www.businesswire.com

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028: 100+ Drugs In Clinical Trials - Orphan, Fast Track, Breakthrough Therapy Designation Insights - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The market for CD47 inhibitors has both opportunities and challenges. Strong commercial interest and encouraging clinical evidence point to substantial development potential. However, there are challenges to address, such managing toxicity profiles, coming up with the best combination plans, and demonstrating distinct therapeutic advantages over current treatments. As the field develops, biomarker development for response prediction and patient selection will probably become more crucial for clinical development as well as marketing tactics. Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 Report Highlights Global & Regional Market Opportunity Outlook Insight On More Than 100 CD47 Inhibitor Drugs In Clinical Trials Global CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase Orphan, Fast Track, Breakthrough Therapy Designation Insight Key Drugs Initiation & Completion Year CD47 Clinical Application & Development Outlook By Indication CD47 Inhibitor Drugs Clinical Developments & Trends By Country Global CD47 Inhibitor Drug Market Dynamics Inhibition of the cell surface protein CD47 has emerged as a novel cancer immunotherapy approach that has piqued the interest of both academia and industry in the recent years. Cancer cells often overexpress CD47, which triggers the "don't eat me" signal pathway, thereby helping malignant cells to escape immune surveillance. CD47 inhibitors seek to uncover cancer cells by inhibiting this protein, leaving them open to immune system attack, specifically through increased macrophage phagocytosis. Although no CD47 inhibitor is currently approved for therapeutic usage, the availability of candidates in phase 3 trials suggests that one may be approved in the coming years. With multiple candidates at varying stages of development, the field of CD47 inhibitor research and development is rapidly evolving. Developed by Forty Seven, which is now a part of Gilead, magrolimab is among the most advanced CD47 inhibitors. In early stage clinical trials for hematological tumors, it has demonstrated encouraging outcomes, especially when combined with other cancer treatments. Furthermore, late stage clinical trials evaluating Magrolimab in solid cancer alongside conventional cancer treatments such as docetaxel, Nivolumab, Pembrolizumab, Azacitidine, and Venetoclax are now under progress. Another significant candidate is Evorpacept (ALX148) from ALX Oncology, a high affinity SIRP fusion protein that inhibits CD47. Currently, evorpacept is being assessed as a monotherapy and in combination with widely used anticancer drugs in a number of early phase clinical trials for a variety of solid and hematological tumors. Furthermore, a late-phase trial evaluating Evorpacept in combination with Trastuzumab, Ramucirumab, and Paclitaxel for the treatment of HER2+ gastric cancer is also under progress. A number of other CD47 inhibitors, including as TQB 2928 (Chia Tai Tianqing Pharmaceutical), MP 0621 (Molecular Partners), IMC-002 (ImmuneOncia Therapeutics), and CC 90002 (Celgene), are in the early phases of clinical research. The emphasis on combination therapies is undoubtedly one of the key trends in clinical development. Combining CD47 inhibitors with other immunotherapies, targeted treatments, and chemotherapy is being studied in an effort to overcome resistance mechanisms and provide synergistic benefits. Anticipated growth in the global market for CD47 inhibitors is attributed to the rising cancer incidence and increased use of immunotherapies in the upcoming years. The potential of CD47 inhibitors has been acknowledged by a number of prominent pharmaceutical companies, which has resulted in notable partnerships and acquisitions. The commercial interest in this field is demonstrated by Gilead Science's US$ 4.9 billion acquisition of Forty Seven in 2020 and Pfizer's US$ 2.26 billion acquisition of Trillium Therapeutics in 2021. Although Chinese and American companies presently dominate the market, there is increasing participation from South Korea, Australia, Canada, and Japan. Through clinical research, companies such as Shaperon, InnobationBio, Bitterroot Bio, and ImmuneOncia Therapeutics are making strides with their CD47 inhibitors. The market is becoming increasingly competitive, with several firms striving for market share. Therefore, for commercial success, differentiation based on safety profile, efficacy, and possible combination strategies will be essential. In conclusion, the market for CD47 inhibitors globally is an active rapidly expanding area of cancer immunotherapy. In the years to come, CD47 inhibitors could have a big impact on cancer therapy paradigms because there are several candidates in clinical development and a lot of commercial interest. Key Topics Covered: 1. CD 47 As Novel Cancer Immunotherapy Target 2. Global CD47 Inhibitors Drug Clinical Pipeline Overview 2.1 By Country 2.2 By Company 2.3 By Indication 2.4 By Patient Segment 2.5 By Phase 2.6 By Priority Status 3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase 3.1 Research 3.2 Preclinical 3.3 Phase I 3.4 Phase I/II 3.5 Phase II 3.6 Phase II/III 3.7 Phase III 4. Global CD47 Inhibitor Drug Market Opportunity Outlook 4.1 Current Market Overview 4.2 Future Outlook & Opportunities 5. CD47 Clinical Application & Development Outlook by Indication 5.1 Solid Cancers 5.1.1 Breast Cancer 5.1.2 Colorectal Cancer 5.1.3 Lung Cancer 5.1.4 Urogenital Cancer 5.1.5 Gastrointestinal Cancer 5.2 Hematological Malignancies 5.2.1 Lymphoma 5.2.2 Leukemia 5.2.3 Multiple Myeloma 5.2.4 Myelodysplastic Syndrome 5.3 Microbial Infections 6. CD47 Inhibitor Drugs Clinical Developments & Trends By Country 6.1 China 6.2 US 6.3 South Korea 6.4 Australia 6.5 Canada 7. Global CD47 Inhibitors Market Dynamics 7.1 Favorable Parameters 7.2 Market Restraints 8. Competitive Landscape 8.1 Adagene 8.2 ALX Oncology 8.3 ImmuneOncia Therapeutics 8.4 ImmuneOnco Biopharma 8.5 Light Chain Bioscience 8.6 Phanes Therapeutics 8.7 Virtuoso Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/z9gctb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ImmunotherapyAcquisitionClinical StudyFast TrackPhase 3

24 Jan 2025

·endpts.com

ALX Oncology to make case for accelerated approval with new evorpacept data in gastric cancer

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential accelerated approval pathway for its CD47-targeting drug in gastric cancer after reporting more data from a Phase 2 trial. The biotech believes it may have a case for a speedier regulatory path or a Phase 3 trial with a “relatively tight” design, CEO Jason Lettmann told Endpoints News in an interview. This comes after last summer’s topline data readout that turned out to be less impressive than a previous interim readout . According to Phase 2 data presented Thursday at the ASCO Gastrointestinal Cancers Symposium in San Francisco, evorpacept plus Roche’s Herceptin, Eli Lilly’s Cyramza and paclitaxel chemotherapy reached 9.5 months of median progression-free survival in 48 patients with fresh HER2-positive biopsies versus 7.1 months for the three-drug control. But in the open-label trial, the difference in median PFS in the broader intent-to-treat population of 127 patients was much less marked, with the treatment arm hitting 7.5 months versus 7.4 months for the control group. There were a “significant number of patients who were HER2-negative” in the ITT group because they had an old biopsy, Lettmann told Endpoints. “To be blunt, our drug will not work very well when we don’t have HER2 expression,” he said. Hello, Debbie Peters You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? Hello, Debbie Peters You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? The company’s share price $ALXO was down by as much as 16% Thursday morning. Thursday’s data join a topline readout in July 2024, which showed the evorpacept regimen attained a 40.3% overall response rate versus 26.6% for control, with a p-value of 0.027. The ORR for the treatment arm was even higher in patients with fresh biopsies at 54.8%. At the time, ALX said it would start a Phase 3 trial by the end of 2024. But Lettmann explained that “we wanted to see PFS mature and we wanted to see this biomarker story fully fleshed out — we now have both of those.” The biotech expects to share details on Phase 3 timings and details after it gets more clarity from the FDA in the second quarter. Evorpacept belongs to a troubled drug class. Several other CD47 contenders have been dropped by their developers due to serious safety issues, often involving infections or respiratory side effects. These ill-fated candidates include Gilead’s magrolimab , which it acquired back in 2020 as part of a $4.9 billion buyout of Forty Seven. In the Phase 2 trial, the evorpacept combination was well-tolerated. ALX believes that evorpacept’s silenced Fc demain and the company’s specific choice of combinations could help avoid the usual pitfalls. “We block the ‘don’t eat me’ signal, and then we use an Fc-active antibody like Herceptin to provide the ‘eat me’ signal — we need both of those things working together to then drive efficacy,” Lettmann said.

Phase 2Clinical ResultPhase 3Acquisition

17 Dec 2024

·www.fiercebiotech.com

Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact

This comes amid a tough 2024 for Gilead\'s historic R&D deals. \n Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B raise for its artificial intelligence (AI) drug discovery work, and now it’s heading into the holidays with a new research pact with Gilead.Details are thin on the ground, but we know Gilead is tapping into Terray’s so-called tNova platform, the startup’s generative AI.This platform is designed to improve the speed, cost and success rate of drug development. So far, tNova has helped Terray measure more than 5 billion target-ligand interactions over the last three years, a figure the biotech believes is about 50 times larger than all publicly available chemistry data. The promise of the approach was enough for that series B back in mid-October (and a $60 million raise in 2022), and now Gilead wants in, signing up to tap the tNova platform to “discover and develop small molecule compounds against a set of targets selected by Gilead,” according to a Dec. 17 press release.Neither company was forthcoming on financial details or targets, with Gilead simply saying that—should it tap its option to exclusively license the compounds—it “will be responsible for further development and commercialization activities for products resulting from the collaboration.”Terray gets an upfront payment and is in line for biobucks and sales milestones, though figures for these were not made public.Gilead joins Bristol Myers Squibb and Alphabet subsidiary Calico in working with the startup.“Next-generation, AI-driven platforms using custom-generated large, relevant data sets will serve as important tools in our efforts to shape the future of drug discovery in our ongoing pursuit of innovative treatments across our therapeutic areas of focus,” Flavius Martin, M.D., Executive Vice President, Research, Gilead, said in the release.“We are excited to collaborate with Terray and explore how their integrated discovery platform will complement our own internal research capabilities and expertise.”This comes after a bumpy year for Gilead’s research pacts. It’s been forced to give up on several projects in 2024, including in early MASH development and, more painfully, on the anti-CD47 monoclonal antibody magrolimab, which it bought in a $4.9 billion deal in 2020, leaving a major financial hole.Only last month, the company announced it was culling 72 workers in Seattle while also outlining plans to shutter an R&D support site.

Acquisition

100 Deals associated with Magrolimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11846	-	-	DB16225

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	United States	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Japan	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Australia	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Austria	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Belgium	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Canada	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Denmark	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	France	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Germany	Gilead Sciences, Inc.	01 Jul 2021
Acute Myeloid Leukemia	Phase 3	Hong Kong	Gilead Sciences, Inc.	01 Jul 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05079230 (ENHANCE-3, CTgov)	Phase 3	Acute Myeloid Leukemia	378	Venetoclax+Magrolimab+Azacitidine (Magrolimab + Venetoclax + Azacitidine)	fvsngjvxhn(uzzqqkosod) = pvkijdhude elbhwdbomz (ngxivdjado, kykiwcdejl - vhxgitldvc) View more	-	04 Apr 2025
				Placebo+Venetoclax+Azacitidine (Magrolimab Matching Placebo + Venetoclax + Azacitidine)	fvsngjvxhn(uzzqqkosod) = bumfjucyzf elbhwdbomz (ngxivdjado, lpgtxtkhuw - wuzpklbwnd) View more
NCT04778397 (ENHANCE-2, CTgov)	Phase 3	Acute Myeloid Leukemia	258	Magrolimab+Azacitidine	mznbgsbmwy(hjjcamsmqd) = gimazakouq lhoqlcseam (kxzcugmnxf, mqyxrjejyj - iweonyaaet) View more	-	05 Feb 2025
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	Magrolimab in combination with Venetoclax and Azacitidine	rszkjvmdrp(kfiyppwpgl) = Deaths related to pneumonia or lung disease (N=3 vs N=1) and disease progression (N=10 vs N=6) in were increased in the magrolimab arm compared to placebo zlaspaysdn (rjorkplytv ) View more	-	08 Dec 2024
				Placebo
NCT02953509 (Pubmed \| Blood Adv) Manual	Phase 1/2	Diffuse Large B-Cell Lymphoma	132	Magrolimab plrituximabmab	ahdgzzjsvr(fknfvygzfk) = nncsqtgfwu hcmelypvwn (nerlblmlvv ) View more	Positive	26 Nov 2024
				Magrolimab plrituximabmabgemcitabinetaboxaliplatinatin	ahdgzzjsvr(fknfvygzfk) = ywyvsrtxln hcmelypvwn (nerlblmlvv ) View more
NCT02953509 (phase 1/2 trial, Pubmed \| Blood Adv) Manual	Phase 1/2	Non-Hodgkin Lymphoma	46	Magrolimabrituximab	dwngnkkkcz(dlsxphyenu) = rrzqdiqqxh nttpbheecr (wyqebqtffh ) View more	Positive	26 Nov 2024
NCT04827576 (ELEVATE-Lung and UC, SITC2024)	Phase 2	metastatic non-small cell lung cancer CD47 \| ctDNA	29	Magrolimab plus docetaxel	dbygwheiia(stfqwkhiuo) = CD47 expression in pre-treatment biopsies was highly variable, with H-scores ranging from 0 to 300 (median 127.5). Real world data from Tempus Labs, Inc. indicates that high CD47 gene expression is a positive prognostic factor for response to chemotherapy in NSCLC. In our study, longer ORR and PFS was also associated with higher CD47 expression by IHC. Patients with CD47 expression above 50% of tumor cells demonstrated an ORR of 36.4% with corresponding PFS of 8.9 months. bqpnpplowe (mikjfkomje )	Positive	05 Nov 2024
NCT04827576 (604, SITC2024)	Phase 2	metastatic non-small cell lung cancer cluster of differentiation 47 (CD47)	-	Magrolimab + Docetaxel	rapmhsfdmd(oxxeiwnveq) = zyqrwtmfsi uercukuvor (fgydcnapjr )	Positive	05 Nov 2024
NCT05079230 (ENHANCE-3, EHA 12024 \| EHA 22024) Manual	Phase 3	Acute Myeloid Leukemia First line	378	Magrolimab +Azacitidine + Venetoclax	jmqhuuawdi(xciksheyqd) = utktzkstgd keublfuvgi (obnigxengh ) View more	Negative	14 May 2024
				Placebo + Azacitidine + Venetoclax	jmqhuuawdi(xciksheyqd) = kdqmzruucz keublfuvgi (obnigxengh ) View more
NCT04778410 (EHA2024) Manual	Phase 2	Acute myeloid leukemia with multilineage dysplasia CD47	36	Magrolimab mitoxantroneetoposidecytarabine	nstrrzuuma(blwkdutemo) = btjiawwhas eqfrlwfyfc (oprrzfrclm )	Positive	14 May 2024
NCT04313881 (ENHANCE, EHA 12024 \| EHA 22024) Manual	Phase 3	High Risk Myelodysplastic Syndrome First line	539	Magrolimab + Azacitidine	svtfacewsf(mndeaqddwz) = tndtudamcc jajgzjgfjc (pdqfricqmp ) Not Met View more	Negative	14 May 2024
				Placebo + Azacitidine	svtfacewsf(mndeaqddwz) = rdxwbmwxcx jajgzjgfjc (pdqfricqmp ) Not Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis